Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02787369Phase 1Active Not Recruiting

ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL

Role: collaborator

NCT02091063Phase 1Terminated

ACY-1215 for Relapsed/Refractory Lymphoid Malignancies

Role: collaborator

NCT02632071Phase 1Completed

ACY-1215 + Nab-paclitaxel in Metastatic Breast Cancer

Role: collaborator

NCT02088398Phase 1Completed

Alternative 10 mg/mL Liquid Formulation of ACY 1215 (Ricolinostat) in Healthy Subjects

Role: lead

All 4 trials loaded